Molecular imaging in hereditary forms of parkinsonism

The development of in vivo molecular imaging to evaluate the dopamine (DA) system with positron‐emission tomography and single photon emission computed tomography has been of key importance on monitoring in vivo nigrostriatal neuronal loss in Parkinson's disease (PD), mostly through assessments of pre‐ and post‐synaptic DA receptors. The discoveries of genes related to hereditary forms of parkinsonism (PARK1, PARK2, PARK6, PARK7 and PARK8) have increased our understanding either of distinct subtypes of clinical expression in PD or its etiology. This article revises current data on molecular neuroimaging of genetic forms of parkinsonism comparing and contrasting its main features with the classical sporadic forms. Awareness of the spectrum variance in the genotype and its respective PD phenotype are useful to distinguish different pathophysiological mechanisms of PD.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  E. Amaro,et al.  Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?—A [99mTc]‐TRODAT‐1 SPECT study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[3]  S. Tufik,et al.  Neuroimagem do transportador de dopamina na doença de Parkinson: primeiro estudo com [99mTc]-TRODAT-1 e SPECT no Brasil , 2006 .

[4]  A. Antonini,et al.  Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation , 2006, Movement disorders : official journal of the Movement Disorder Society.

[5]  N. Quinn,et al.  Upregulation of dopamine D2 receptors in dopaminergic drug‐naive patients with parkin gene mutations , 2006, Movement disorders : official journal of the Movement Disorder Society.

[6]  M. Toft,et al.  Parkinson's disease: the genetics of a heterogeneous disorder , 2006, European journal of neurology.

[7]  R. Bressan,et al.  Parkinson's disease and dopamine transporter neuroimaging: a critical review. , 2006, Sao Paulo medical journal = Revista paulista de medicina.

[8]  Anette Schrag,et al.  Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism , 2006, The Lancet Neurology.

[9]  Michele T. M. Hu,et al.  Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin‐linked Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[10]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[12]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[13]  D. Grosset,et al.  The role of radiotracer imaging in Parkinson disease , 2005, Neurology.

[14]  N. Wood,et al.  Molecular genetic pathways in Parkinson's disease: a review. , 2005, Clinical science.

[15]  P. Tienari,et al.  How useful is [123I]β-CIT SPECT in clinical practice? , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[17]  C. Klein,et al.  Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes , 2005, Neurology.

[18]  Juha O. Rinne,et al.  Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson's disease , 2005, Neurobiology of Aging.

[19]  S. Przedborski.  Pathogenesis of nigral cell death in Parkinson's disease. , 2005, Parkinsonism & related disorders.

[20]  Y. Hsin,et al.  Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. , 2005, Parkinsonism & related disorders.

[21]  K. Kessler,et al.  Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson’s syndrome , 2005, Journal of Neural Transmission.

[22]  Janel O. Johnson,et al.  Clinical and positron emission tomography of Parkinson's disease caused by LRRK2 , 2005, Annals of neurology.

[23]  Deborah B. Goldberg.  Somatoform Disorders: A Medicolegal Guide , 2005 .

[24]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[25]  D. Brooks,et al.  Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation , 2005, Neurology.

[26]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[27]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[28]  N. Hattori,et al.  PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations , 2004, Neurology.

[29]  R. Krüger,et al.  Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) , 2004, Human mutation.

[30]  A. Bentivoglio,et al.  PINK1 mutations are associated with sporadic early‐onset parkinsonism , 2004, Annals of neurology.

[31]  Richard S. Frackowiak,et al.  PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences , 2004, NeuroImage.

[32]  P. Piccini.  Neurodegenerative movement disorders: the contribution of functional imaging , 2004, Current opinion in neurology.

[33]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Nicola Pavese,et al.  Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. , 2004, Brain : a journal of neurology.

[35]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[36]  A. Antonini,et al.  PET and SPECT functional imaging in Parkinson's disease. , 2004, Sleep medicine.

[37]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[38]  W. Oertel,et al.  Role of dopamine transporter SPECT for the practitioner and the general neurologist , 2003, Movement disorders : official journal of the Movement Disorder Society.

[39]  Vladimir N Uversky,et al.  A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders , 2003, Journal of biomolecular structure & dynamics.

[40]  K. Leenders.  Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[41]  Alexandra Durr,et al.  How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.

[42]  C. V. van Duijn,et al.  Parkinson's disease: piecing together a genetic jigsaw. , 2003, Brain : a journal of neurology.

[43]  Vincenzo Bonifati,et al.  Clinical features and neuroimaging of PARK7‐linked parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.

[44]  Nicolas Costes,et al.  Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. , 2003, Archives of neurology.

[45]  Paola Piccini,et al.  Clinical and subclinical dopaminergic dysfunction in PARK6‐linked parkinsonism: An 18F‐dopa PET study , 2002, Annals of neurology.

[46]  C. Nahmias.  Molecular imaging: the next frontier. , 2002, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[47]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[48]  Nicola Pavese,et al.  Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. , 2002, Brain : a journal of neurology.

[49]  F. Fazio,et al.  Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2) , 2002, Neurological Sciences.

[50]  R. Marconi,et al.  Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7 , 2002, Neurological Sciences.

[51]  Karl Herholz,et al.  The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.

[52]  C. Goetz,et al.  Parkin mutations in a patient with hemiparkinsonism–hemiatrophy: A clinical–genetic and PET study , 2002, Neurology.

[53]  J. Seibyl,et al.  [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.

[54]  J. Houwing-Duistermaat,et al.  Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. , 2001, American journal of human genetics.

[55]  D. Dickson,et al.  Alpha-synuclein and the Lewy body disorders. , 2001, Current opinion in neurology.

[56]  Merja Haaparanta,et al.  Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study , 2001, Movement disorders : official journal of the Movement Disorder Society.

[57]  K L Leenders,et al.  The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations , 2001, Neurology.

[58]  N. Hattori,et al.  An apparently sporadic case with parkin gene mutation in a Korean woman. , 2001, Archives of neurology.

[59]  R. P. Maguire,et al.  Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers , 2001 .

[60]  W D Heiss,et al.  Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial Parkinsonism associated with mutations in the Parkin gene , 2001, Annals of neurology.

[61]  A Dürr,et al.  [18F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations , 2000, Neurology.

[62]  N. Hattori,et al.  Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification , 2000, Brain and Development.

[63]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[64]  Bonifati,et al.  Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.

[65]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[66]  Vesna Sossi,et al.  Prevalence of epilepsy in rural Bolivia , 1999, Neurology.

[67]  T. Hosoya,et al.  Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted MR imaging. , 1999, AJNR. American journal of neuroradiology.

[68]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[69]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[70]  M. Polymeropoulos,et al.  Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.

[71]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[72]  B. Snow.  Positron Emission Tomography in Parkinson’s Disease , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[73]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[74]  C Nahmias,et al.  Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.

[75]  J. Degroot,et al.  Magnetic resonance imaging of the midbrain in Parkinson's disease , 1986, Annals of neurology.

[76]  E. Amaro,et al.  [Neuroimaging of the dopamine transporter in Parkinsons disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil]. , 2006, Arquivos de neuro-psiquiatria.

[77]  R A Koeppe,et al.  Imaging the vesicular monoamine transporter. , 2001, Advances in neurology.

[78]  V Sossi,et al.  PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. , 1999, Neurology.

[79]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.